AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00387322
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00387322
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01542138
Drug: Desonide
RxNorm normalized name: Desonide
DrugBank: Desonide (DB01260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-a-day applying on axillar hyperpigmentation for 9 weeks
Trial: NCT01542138
Drug: Niacinamide
RxNorm normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-a-day applying on axillar hyperpigmentation for 9 weeks
Trial: NCT00441285
Drug: Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
Trial: NCT00441285
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.
Trial: NCT04449289
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
Trial: NCT04449289
Drug: Epidural ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
Trial: NCT00911937
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4mg and 8 mg tablets taken daily.
Trial: NCT03898037
Drug: metformin intervention
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
Trial: NCT02797431
Drug: Interleukin-7
RxNorm normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Trial: NCT04428268
Drug: Chloroquine Phosphate Tablets
RxNorm normalized name: Chloroquine Phosphate Tablets
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered
Trial: NCT02814110
Drug: Granulocyte colony-stimulating factor (Filgrastim)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug administration
Trial: NCT01351818
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168051
Drug: ReFacto
RxNorm normalized name: ReFacto
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01870908
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01870908
Drug: biological agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232607
Drug: Lacidipine, low dose
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232607
Drug: Lacidipine, medium dose
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232607
Drug: Lacidipine, high dose
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00655551
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
Trial: NCT01316718
Drug: Mesalazine
RxNorm normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
Trial: NCT00655551
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
Trial: NCT00655551
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
Trial: NCT00502567
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion
Trial: NCT00502567
Drug: Irinotecan (administered with & without Cetuximab)
RxNorm normalized name: Cetuximab
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous injection
Trial: NCT00502567
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT02076620
Drug: L19TNFα
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
Trial: NCT00094991
Drug: Muraglitazar
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029872
Drug: Chlorhexidine gluconate soap
RxNorm normalized name: chlorhexidine gluconate Soap Product
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine gluconate (soap)
Trial: NCT02029872
Drug: Chlorhexidine gluconate oral rinse
RxNorm normalized name: Chlorhexidine Gluconate Oral Rinse
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chlorhexidine gluconate oral rinse 0.12%
Trial: NCT01493427
Drug: Travoprost 0.004%
RxNorm normalized name: TRAVOPROST 0.004% SOLN,OPH
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
Trial: NCT02449369
Drug: Postop hydromorphone IV
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02449369
Drug: Postop oral orphenadrine
DrugBank: Orphenadrine (DB01173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002935
Drug: porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02223351
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02084511
Drug: BI 1026706
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1026706
Trial: NCT01562977
Drug: Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
Trial: NCT02449369
Drug: Postop oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02449369
Drug: Postop orphenadrine IV
DrugBank: Orphenadrine (DB01173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00887484
Drug: BENZOYL PEROXIDE/ ADAPALENE
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
Trial: NCT02275975
Drug: K-877
RxNorm normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02275975
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01939314
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
Trial: NCT02993198
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01859988
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01783964
Drug: [14C]-Elacytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intravenous administration
Trial: NCT01072630
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
Trial: NCT02065687
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02065687
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02065687
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04260516
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucolytic and antioxidant drug
Trial: NCT01998503
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01998503
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT01998503
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01346670
Drug: LipoCol and Mevacor
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
Trial: NCT00492726
Drug: Moxifloxacin (Avelox, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin, 400mg, administered intravenously once daily
Trial: NCT00492726
Drug: Ertapenem intravenous
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active treatment: Ertapenem 1.0g, administered intravenously once daily
Trial: NCT00254514
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01590108
Drug: (Pyr1)apelin-13
RxNorm normalized name: Apelin
DrugBank: Apelin (DB18909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
Trial: NCT01590108
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03914638
Drug: Salbutamol 4Mg Tablet
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg, three times daily
Trial: NCT00001145
Drug: KLH
RxNorm normalized name: KLH
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03888157
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
Trial: NCT04411160
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
Trial: NCT02217475
Drug: Cenicriviroc
RxNorm normalized name: Cenicriviroc
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC 150 mg, administered orally once daily and taken every morning with food.
Trial: NCT02145559
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02145559
Drug: Delayed Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02145559
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00720590
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
Trial: NCT02703259
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02072785
Drug: Vincristine Sulfate Liposome
RxNorm normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02072785
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00148070
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
Trial: NCT02311231
Drug: bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
Trial: NCT02485067
Drug: Detrusitol 2mg tablet
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine 2mg
Trial: NCT03928340
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy
Trial: NCT03262142
Drug: Piperacillin/tazobactam
RxNorm normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Piperacillin/tazobactam four times daily
Trial: NCT03262142
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ciprofloxacin twice daily
Trial: NCT00890643
Drug: prazosin hydrochloride
RxNorm normalized name: Prazosin Hydrochloride
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prazosin 1-20 mg/day in divided doses
Trial: NCT00625547
Drug: cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
Trial: NCT03928340
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
Trial: NCT02818725
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PANITUMUMAB: 6 mg/kg on day 2
Trial: NCT03302078
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed state
Trial: NCT03302078
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted state
Trial: NCT02971761
Drug: Enobosarm
RxNorm normalized name: enobosarm
DrugBank: Enobosarm (DB12078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00313625
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01608880
Drug: nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
Trial: NCT01608880
Drug: Polysporin ointment
RxNorm normalized name: Polysporin Ointment
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
Trial: NCT01604889
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00313625
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00313625
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04493463
Drug: Ropivacaine + Saline
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
Trial: NCT01604889
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg IV
Trial: NCT01604889
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doses to be determined following the completion of Phase I of the study
Trial: NCT02322749
Drug: selumetinib 75mg single dose
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 blue capsules of 25 mg given as a single dose
Trial: NCT02322749
Drug: selumetinib 75mg single dose
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 capsules of 25 mg given as a single dose
Trial: NCT01551459
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
Trial: NCT01551459
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
Trial: NCT03803839
Drug: Clodronate
RxNorm normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03803839
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00289861
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no